


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Paul J. Maddon et al.  
Serial No.: 10/695,667  
Confirmation No.: 4456  
Filed: October 27, 2003  
For: PSMA FORMULATIONS AND USES THEREOF  
Examiner: S. L. Rawlings  
Art Unit: 1643

<b>Certificate of Electronic Filing Under 37 CFR 1.8</b>	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).	
Dated: April 10, 2009	Signature:  (Michelle M. Quinn)

**RESPONSE TO ELECTION OF SPECIES REQUIREMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Madam:

In response to the species election requirement, applicant hereby elects the species of PSMA protein: amino acids 44-750 of SEQ ID NO:1 and the species of pH: pH 7. At least claims 48, 52, 55, 56, 59-61, 63-90, 187-198, 199 (in part), 200-208, 210, 212-236, 237 (in part), 238-250, 252-258, 259 (in part) and 260-265 are believed to represent a grouping of claims representative of the elected species. Applicant's election is made without traverse.

Nevertheless, Applicant makes the following comments for the record. Applicant notes that the Examiner has not completely characterized the originally presented claims and currently pending claims correctly. The originally presented claims were directed, at least in part, to compositions comprising isolated PSMA protein, wherein a percentage of which is an isolated PSMA protein multimer. The term "PSMA protein" includes full-length PSMA or a portion thereof. The isolated PSMA protein multimer, in some embodiments, was an isolated PSMA


protein dimer. Said dimer, in some embodiments, comprised a fragment of full-length PSMA, which, in some embodiments, was the extracellular portion or a fragment thereof. The currently pending claims are directed, at least in part, to compositions comprising an isolated dimer of PSMA protein, wherein each protein comprises the full-length protein or a portion thereof. In some embodiments, this portion is 44-750, 58-750 or 601-750 of SEQ ID NO:1. In addition, Applicant notes that the claims as pending just prior to the Examiner's first office action on the merits also included at least a pH ranging from 6 to 6.5.

Applicant's election is made without prejudice and without conceding the correctness of the restriction requirement or the Examiner's arguments presented therein. As noted by the Examiner, upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which depend from or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141.

If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicants hereby request any necessary extension of time. If there is a fee occasioned by this response, that is not covered by any provided payment, please charge the fee or deficiency to Deposit Account No. 23/2825 under Order No. P0741.70006US00 from which the undersigned is authorized to draw.

Dated: April 10, 2009

Respectfully submitted,

By   
Janice A. Vatland, Ph.D.  
Registration No.: 52,318  
WOLF, GREENFIELD & SACKS, P.C.  
Federal Reserve Plaza  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
617.646.8000